비전이성 전립선암 치료법으로서의 CyberKnifeTM
CyberKnifeTM for the Treatment of Non-Metastatic Prostate Cancer
이승준, 송강현, 박종욱, 길명철, 조문기,
소속 상세정보
이승준 ( Lee Seung-Joon )
원자력병원 비뇨기과
송강현 ( Song Kang-Hyon )
원자력병원 비뇨기과
박종욱 ( Park Jong-Wook )
원자력병원 비뇨기과
길명철 ( Gil Myung-Cheol )
원자력병원 비뇨기과
조문기 ( Jo Moon-Ki )
원자력병원 비뇨기과
KMID : 0358320090500080744
Abstract
Purpose: The radiobiology of prostate cancer favors a hypofractionated dose regimen. We report here our experience with the CyberKnifeTM, demonstrating its efficacy, safety, and feasibility as a treatment modality for non-metastatic prostate cancer.
Materials and Methods: Between October 2002 and April 2006, 20 patients with biopsy-proven prostate cancer were treated with the CyberKnifeTM. The distribution of clinical risks, as assessed by using D’Amico’s definition for risk grouping, was as follows: low (4), intermediate (5), and high (11). Three patients received 32 Gy, 7 patients received 34 Gy, and 10 patients received 36 Gy. All patients received the radiation doses in 4 fractions. The rectal and bladder toxicities were graded by using the criteria set forth by the Radiation Therapy Oncology Group (RTOG).
Results: The mean patient age was 71.4 years (range, 52-79 years), and the mean follow-up period was 35.5 months (range, 8-74 months). There were 2 acute and 1 late grade 2 gastrointestinal toxicities, and 1 acute and 2 late grade 2 urinary toxicities. The 5-year overall survival rate was 100%, respectively. The 5-year biochemical failure-free rate of the low-risk, intermediate-risk, and high-risk patients was 100%, 100%, and 90.9%, respectively.
Conclusions: CyberKnifeTM is a safe, well-tolerated, and rather effective treatment for non-metastatic prostate cancer. We obtained a 100% 5-year biochemical failure-free rate in low-risk and intermediate-risk patients. CyberKnifeTM is a viable option for the treatment of non-metastatic prostate cancer.
키워드
Prostatic neoplasms;Radiation;Radiosurgery
원문 및 링크아웃 정보
등재저널 정보